Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.
Neprilysin (NEP) is an endogenous protease that degrades a wide range of peptides including amyloid beta (Aβ), the main pathological component of Alzheimer's disease (AD). We have engineered NEP as a potential therapeutic for AD but found in pre-clinical safety testing that this variant increas...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4954676?pdf=render |
id |
doaj-e66447b42ce24666aee4005e9eeeb96b |
---|---|
record_format |
Article |
spelling |
doaj-e66447b42ce24666aee4005e9eeeb96b2020-11-25T02:27:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01117e015811410.1371/journal.pone.0158114Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.Matthew BurrellSimon J HendersonAnna RavnefjordFritz SchweikartSusan B FowlerSusanne WittKenny M HanssonCarl I WebsterNeprilysin (NEP) is an endogenous protease that degrades a wide range of peptides including amyloid beta (Aβ), the main pathological component of Alzheimer's disease (AD). We have engineered NEP as a potential therapeutic for AD but found in pre-clinical safety testing that this variant increased prothrombin time (PT) and activated partial thromboplastin time (APTT). The objective of the current study was to investigate the effect of wild type NEP and the engineered variant on coagulation and define the mechanism by which this effect is mediated. PT and APTT were measured in cynomolgus monkeys and rats dosed with a human serum albumin fusion with an engineered variant of NEP (HSA-NEPv) as well as in control plasma spiked with wild type or variant enzyme. The coagulation factor targeted by NEP was determined using in vitro prothrombinase, calibrated automated thrombogram (CAT) and fibrin formation assays as well as N-terminal sequencing of fibrinogen treated with the enzyme. We demonstrate that HSA-NEP wild type and HSA-NEPv unexpectedly impaired coagulation, increasing PT and APTT in plasma samples and abolishing fibrin formation from fibrinogen. This effect was mediated through cleavage of the N-termini of the Aα- and Bβ-chains of fibrinogen thereby significantly impairing initiation of fibrin formation by thrombin. Fibrinogen has therefore been identified for the first time as a substrate for NEP wild type suggesting that the enzyme may have a role in regulating fibrin formation. Reductions in NEP levels observed in AD and cerebral amyloid angiopathy may contribute to neurovascular degeneration observed in these conditions.http://europepmc.org/articles/PMC4954676?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matthew Burrell Simon J Henderson Anna Ravnefjord Fritz Schweikart Susan B Fowler Susanne Witt Kenny M Hansson Carl I Webster |
spellingShingle |
Matthew Burrell Simon J Henderson Anna Ravnefjord Fritz Schweikart Susan B Fowler Susanne Witt Kenny M Hansson Carl I Webster Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen. PLoS ONE |
author_facet |
Matthew Burrell Simon J Henderson Anna Ravnefjord Fritz Schweikart Susan B Fowler Susanne Witt Kenny M Hansson Carl I Webster |
author_sort |
Matthew Burrell |
title |
Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen. |
title_short |
Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen. |
title_full |
Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen. |
title_fullStr |
Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen. |
title_full_unstemmed |
Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen. |
title_sort |
neprilysin inhibits coagulation through proteolytic inactivation of fibrinogen. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
Neprilysin (NEP) is an endogenous protease that degrades a wide range of peptides including amyloid beta (Aβ), the main pathological component of Alzheimer's disease (AD). We have engineered NEP as a potential therapeutic for AD but found in pre-clinical safety testing that this variant increased prothrombin time (PT) and activated partial thromboplastin time (APTT). The objective of the current study was to investigate the effect of wild type NEP and the engineered variant on coagulation and define the mechanism by which this effect is mediated. PT and APTT were measured in cynomolgus monkeys and rats dosed with a human serum albumin fusion with an engineered variant of NEP (HSA-NEPv) as well as in control plasma spiked with wild type or variant enzyme. The coagulation factor targeted by NEP was determined using in vitro prothrombinase, calibrated automated thrombogram (CAT) and fibrin formation assays as well as N-terminal sequencing of fibrinogen treated with the enzyme. We demonstrate that HSA-NEP wild type and HSA-NEPv unexpectedly impaired coagulation, increasing PT and APTT in plasma samples and abolishing fibrin formation from fibrinogen. This effect was mediated through cleavage of the N-termini of the Aα- and Bβ-chains of fibrinogen thereby significantly impairing initiation of fibrin formation by thrombin. Fibrinogen has therefore been identified for the first time as a substrate for NEP wild type suggesting that the enzyme may have a role in regulating fibrin formation. Reductions in NEP levels observed in AD and cerebral amyloid angiopathy may contribute to neurovascular degeneration observed in these conditions. |
url |
http://europepmc.org/articles/PMC4954676?pdf=render |
work_keys_str_mv |
AT matthewburrell neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen AT simonjhenderson neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen AT annaravnefjord neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen AT fritzschweikart neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen AT susanbfowler neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen AT susannewitt neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen AT kennymhansson neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen AT carliwebster neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen |
_version_ |
1724841483059593216 |